1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Squamous Non-Small Cell Lung Cancer-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Squamous Non-Small Cell Lung Cancer-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Squamous Non-Small Cell Lung Cancer. This report provides information on the therapeutic development based on the Squamous Non-Small Cell Lung Cancer dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Squamous Non-Small Cell Lung Cancer
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Squamous Non-Small Cell Lung Cancer-Pipeline Insights, 2014
Table of Contents
- Squamous Non-Small Cell Lung Cancer Overview
- Squamous Non-Small Cell Lung Cancer Pipeline Therapeutics
- Squamous Non-Small Cell Lung Cancer Therapeutics under Development by Companies
- Squamous Non-Small Cell Lung Cancer Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Squamous Non-Small Cell Lung Cancer Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Squamous Non-Small Cell Lung Cancer Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Squamous Non-Small Cell Lung Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Squamous Non-Small Cell Lung Cancer - Discontinued Products
- Squamous Non-Small Cell Lung Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Squamous Non-Small Cell Lung Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Squamous Non-Small Cell Lung Cancer, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Squamous Non-Small Cell Lung Cancer Assessment by Monotherapy Products
- Squamous Non-Small Cell Lung Cancer Assessment by Combination Products
- Squamous Non-Small Cell Lung Cancer Assessment by Route of Administration
- Squamous Non-Small Cell Lung Cancer Assessment by Stage and Route of Administration
- Squamous Non-Small Cell Lung Cancer Assessment by Molecule Type
- Squamous Non-Small Cell Lung Cancer Assessment by Stage and Molecule Type
- Squamous Non-Small Cell Lung Cancer Therapeutics - Discontinued Products
- Squamous Non-Small Cell Lung Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Squamous Non-Small Cell Lung Cancer, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Squamous Non-Small Cell Lung Cancer Assessment by Monotherapy Products
- Squamous Non-Small Cell Lung Cancer Assessment by Combination Products
- Squamous Non-Small Cell Lung Cancer Assessment by Route of Administration
- Squamous Non-Small Cell Lung Cancer Assessment by Stage and Route of Administration
- Squamous Non-Small Cell Lung Cancer Assessment by Molecule Type
- Squamous Non-Small Cell Lung Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Pathology Statistics in the US and the UK

  • December 2016
    12 pages
  • Pathology  

    Digestive Syste...  

    Cancer  

  • United States  

    United Kingdom  

View report >

Pathology Statistics in the US and the UK

  • December 2016
    13 pages
  • Pathology  

    Digestive Syste...  

  • United States  

    United Kingdom  

View report >

Digestive System Disorder and Endocrine Disease Statistics in the US

  • December 2016
    4 pages
  • Digestive Syste...  

    Endocrine Disea...  

  • United States  

View report >

Related Market Segments :

Lung Cancer

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.